• Users Online: 105
  • Print this page
  • Email this page

 Table of Contents  
Year : 2021  |  Volume : 1  |  Issue : 4  |  Page : 873

Resolution of angle new vessel

Glaucoma Services, Aravind Eye Hospital, Coimbatore, Tamil Nadu, India

Date of Web Publication09-Oct-2021

Correspondence Address:
Dr. Premanand Chandran
Aravind Eye Hospital, Avinashi Road, Coimbatore - 641 014, Tamil Nadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijo.IJO_389_21

Rights and Permissions

How to cite this article:
Chandran P, Anand AF, Raman GV. Resolution of angle new vessel. Indian J Ophthalmol Case Rep 2021;1:873

How to cite this URL:
Chandran P, Anand AF, Raman GV. Resolution of angle new vessel. Indian J Ophthalmol Case Rep [serial online] 2021 [cited 2021 Dec 5];1:873. Available from: https://www.ijoreports.in/text.asp?2021/1/4/873/327741

A 64-year-old gentleman presented with visual acuity of 20/40 in the right eye (RE) and 20/20 in the left eye (LE). Slit-lamp examination showed neovascularization of iris in both eyes with an intraocular pressure (IOP) of 32 and 16 mmHg in the RE and LE, respectively. Gonioscopy showed open angles in both eyes with neovascularization of the angle in the RE [Figure 1]a. Fundus examination showed hemorrhage and new vessels in the retina, suggestive of proliferative diabetic retinopathy. He underwent intravitreal injection of ranibizumab and panretinal photocoagulation. At the final follow-up, IOP was 16 mmHg on two antiglaucoma medications with the resolution of angle new vessels in the RE [Figure 1]b. Early detection and prompt treatment for angle new vessel will prevent synechiae formation and refractory glaucoma.[1],[2]
Figure 1: Gonioscope photograph showing new vessels in the angle (arrowhead) (a) and resolution of angle new vessels after treatment with anti-vascular endothelial growth factor and panretinal photocoagulation (b)

Click here to view

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 2008;28:696-702.  Back to cited text no. 1
Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142:1054-6.  Back to cited text no. 2


  [Figure 1]


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article
Article Figures

 Article Access Statistics
    PDF Downloaded13    
    Comments [Add]    

Recommend this journal